Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures.
OBJECTIVE
Latanoprost, a prostaglandin F2a analogue and ocular hypotensive agent, alters extracellular matrix and matrix metalloproteinases (MMPs), including MMP-1, within tissues of the uveoscleral outflow pathway. In addition to these tissues, the anterior choroid also is exposed to fluid within the uveoscleral outflow pathway. The present study was undertaken to compare MMP-1 expression in the choroid with other uveoscleral pathway tissues and to determine the effect of latanoprost on MMP-1 expression in human choroid organ cultures.


METHODS
Choroid tissue explant cultures were generated and incubated with PhXA85, the biologically active form of latanoprost, or vehicle for 12 or 18 hours. Explant cultures from iris and ciliary body also were generated and exposed to PhXA85. Protein extracts of theses cultures, as well as from fresh tissues, were then probed for MMP-1 by Western blotting. All samples were normalized for protein content and reletive expression was evaluated by densitometry. Also, total RNA was harvested from fresh tissues or from cultures treated with PhXA85. The amount of MMP-1 mRNA in these samples was measured using real time polymerase chain reaction. These results were normalized according to simultaneous measurements of glyceraldehyde-3-phosphate dehydrogenase mRNA within the same samples.


RESULTS
Compared to the ciliary body, in which specific MMP-1 concentration (/total mg protein) was greatest, the specific MMP-1 concentrations within iris, anterior choroid, and posterior choroid were less by 24.7 +/- 0.69%, 40.7 +/- 1.04%, and 64.5 +/- 0.52%, respectively (mean +/- SD). The order of MMP-1 mRNA expression among these tissues from fresh eyes was ciliary body < anterior choroid < posterior choroid < iris. Treatment of ciliary body explant cultures with 200 nM PhXA85 for 12 hours increased MMP-1 protein content by 154 +/- 34% (P = 0.004, students t test, N = 3). In contrast, similar treatment of anterior choroid, posterior choroid, or iris explant cultures minimally changed MMP-1 protein content (23 +/- 22+/-, P = 0.124; 14 +/- 8%, P = 0.462; 27 +/- 16%, P = 0.037, respectively). Increased MMP-1 was observed in choroid cultures incubated for 18 hrs with 200 nM or 500 nM PhXA85. MMP-1 mRNA in 12 hour PhXA85-treated choroid cultures was the same or less than vehicle-treated cultures from 7 of 9 donors. In contrast, MMP-1 mRNA was increased in PhXA85-treated ciliary body cultures from 2 of 2 donors.


CONCLUSIONS
These results suggest that the capacity for latanoprost-mediated induction of MMP-1 within the choroid is less than within the ciliary muscle. Hence, it is unlikely that induction of MMP-1 in choroid plays as important a role in uveoscleral outflow modulation as induction of MMP-1 in the ciliary muscle.
Wang
N
N
Glaucoma Center, University of California San Diego, La Jolla, California 92093-0946, USA.
Lindsey
J D
JD
Angert
M
M
Weinreb
R N
RN
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western; D002829:Choroid / Q000187:drug effects* / Q000201:enzymology; D002924:Ciliary Body / Q000187:drug effects / Q000201:enzymology; D017931:DNA Primers / Q000737:chemistry; D015342:DNA Probes / Q000737:chemistry; D015237:Dinoprost / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D015151:Immunoblotting; D007498:Iris / Q000187:drug effects / Q000201:enzymology; D000077338:Latanoprost; D020781:Matrix Metalloproteinase 1 / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D009924:Organ Culture Techniques; D016133:Polymerase Chain Reaction; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism
D017931:DNA Primers; D015342:DNA Probes; D011461:Prostaglandins F, Synthetic; D012333:RNA, Messenger; D000077338:Latanoprost; D015237:Dinoprost; D020781:Matrix Metalloproteinase 1; C109345:PhXa 85